Adlai Nortye has dosed the first patient in Australia in the global Phase I trial of AN4035 and received U.S. FDA clearance to expand the study. The milestone gives investors a defined clinical-development path for the company’s CEACAM5-targeting ADC, with full Phase Ia data targeted for the second half of 2027.
Key Highlights
- AN4035 will be tested as a standalone treatment and alongside cetuximab in CEACAM5-enriched, RAS-addicted solid tumors.
- Adlai Nortye is also filing an AN4035 IND application with China’s National Medical Products Administration.
- The U.S. FDA issued a “Study-May-Proceed” letter for AN4035’s investigational new drug application.
Adlai Nortye Group Ltd. (NASDAQ: ANL) has dosed the first patient in Australia in the global Phase I trial of AN4035, its CEACAM5-targeting antibody-drug conjugate. The U.S. Food and Drug Administration has also issued a “Study-May-Proceed” letter for the investigational new drug application, clearing expansion of the study into the United States.
AN4035 Trial Evaluates Safety and Early Activity
Its measures include safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy. The company is also filing an investigational new drug application for AN4035 with China’s National Medical Products Administration. AN4035 uses a pan-RAS(ON) inhibitor payload attached to an antibody that targets CEACAM5. Adlai Nortye said the candidate is designed to deliver the payload selectively to tumors while reducing exposure to normal tissues.
Preclinical testing showed favorable thermal and plasma stability, along with desired pharmacokinetic properties. Compared with the payload alone, the ADC showed greater target-mediated tumor retention and improved tumor selectivity over normal tissues, which the company said resulted in a favorable therapeutic index.
FAQs
Q: What happened with Adlai Nortye’s AN4035 trial?
A: Adlai Nortye dosed the first patient in Australia in its global Phase I AN4035 trial. The U.S. FDA also cleared the investigational new drug application for study expansion.
Q: What will the AN4035 Phase I study evaluate?
A: The study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy. AN4035 will be tested alone and with cetuximab in selected solid tumors.
Q: When will Adlai Nortye report AN4035 data?
A: The company said it remains on track to report full Phase Ia data in the second half of 2027. The filing also states that the trial is being advanced globally after first dosing in Australia and U.S. FDA clearance.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.